Abstract
Objective
The aim of this study was to confirm the most appropriate dosage of a new soft gelatin capsule (SGC) formulation of the HIV protease inhibitor saquinavir by investigating the relationships between systemic (plasma) exposure to saquinavir and plasma HIV RNA and CD4+ cell counts using empirical mathematical modelling.
Design and setting
A randomised, non-blind, multicentre, dose-ranging 8-week study of monotherapy with 400, 800 or 1200mg of saquinavir-SGC or 600mg of the hard gelatin capsule (HGC) formulation, both administered 3 times daily, was carried out in protease inhibitor-naive, HIV-positive adults. Two surrogate markers of response, plasma HIV RNA level and CD4+ cell count, were fitted to 2 measures of systemic drug exposure, the area under the plasma concentration-time curve (AUC) and trough plasma concentration (Cmin), using 6 exposure-response models of progressively increasing complexity. Akaike and Schwarz model selection criteria were applied to determine the most effective pharmacokinetic-pharmacodynamic relationship.
Results
A total of 88 patients were randomised; pharmacokinetic and pharmacodynamic data were available for 84 patients. In terms of plasma HIV RNA, pharmacokinetic-pharmacodynamic relationships were best described by a 2-parameter maximum effect (Emax) model, which predicted a typical maximum reduction in viral load of 1.94 log10 copies/ml [coefficient of variation (CV) 12%], with a half-maximal antiviral response occurring at a Cmin of 50 μ g/L (CV 40%). Saquinavir-SGC 1200mg administered 3 times daily produced a median AUC to 24 hours (AUC24) of approximately 20 000 μg/L · h, corresponding to 85% of the maximum achievable antiviral effect as defined by the model. None of the models yielded a satisfactory fit for CD4+ cell count.
Conclusion
Empirical mathematical modelling confirmed that, when administered 3 times daily, the optimum dose of saquinavir-SGC is 1200mg, corresponding to 3600 mg/day.
Similar content being viewed by others
References
Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334: 1011–7.
Haubrich R, Burger HU, Beattie D, et al. Saquinavir + zalcitabine vs saquinavir or zalcitabine monotherapy in HIV-infected patients discontinuing as intolerant to zidovudine: results of a randomised, double blind trial. AIDS 1996; 10 Suppl. 2: OP4.2.
Stellbrink H-J, Invirase International Phase III Trial (SV-14604) Group. Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients [abstract 2121]. 6th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1997 Oct 11–15; Hamburg.
Vella S, Lazzarin A, Carosi G, et al. A randomised controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antiviral Ther 1996 Aug; 1: 129–40.
Muirhead GJ, Shaw T, Williams PEO, et al. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers [abstract]. Br J Clin Pharmacol 1992 Aug; 34: 170P–1P.
Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93–112.
Schapiro JM, Winters MA, Stewart F, et al. The effect of highdose saquinavir on viral load and CD4 T-cell counts in HTV-infected patients. Ann Intern Med 1996; 124: 1039–50.
Mellors JW, Rinaldo Jr CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167–70.
de Wolf F, Spijkerman I, Schellekens PTh, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after sero-conversion. AIDS 1997; 11: 1799–806.
Schwarz G. Estimating the dimensions of a model. Ann Statistics 1978; 6: 461–4.
Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974; 19: 716–23.
Lalezari J, NV15107 Study Group. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. J AIDS Hum Retrovirol 1998; 19: 195–7.
Sale ME, Blaschke TF. Incorporating pharmacokinetic/pharmacodynamic modelling in drug development: are we ready?. Drug Inf J 1992; 26: 119–24.
Sambol NC, Clementi WA, Sheiner LB. Population dose-response relationships determined from efficacy trials: the antihypertensive effect of atenolol and betaxolol. J Pharmacokinet Biopharm 1991; 19 Suppl. 3: 79S–91S.
Mitsuyasu RT, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS 1998; 12: F103–9.
Vanhove GF, Gries J-M, Verotta D, et al. Exposure-response relationships for saquinavir, zidovudine and zalcitabine in combination therapy. Antimicrobial Agents Chemother 1997; 41: 2433–8.
Kline MW, Fletcher CV, Brundage RC, et al. Combination therapy with saquinavir soft gelatin capsules plus nucleoside anti-retroviral agents in HIV-infected children. 12th World AIDS Conference; 1998 Jun 28–Jul 3; Geneva.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gieschke, R., Fotteler, B., Buss, N. et al. Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive Patients. Clin Pharmacokinet 37, 75–86 (1999). https://doi.org/10.2165/00003088-199937010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199937010-00005